This story reports on a possible relationship between consumption of flavonoids, a compound found in cocoa and many other foods, and improved brain and cardiovascular health. Several lines of evidence are cited, but readers are given little information to determine whether this research is relevant to them. In addition, it is unclear if the cocoa products available to most Americans would improve their brain function at usual consumption patterns. The experts cited describe their own work accurately but do not help put this problem into perspective for the reader. The article attempts only a glancing critique of the evidence. Many of the purported benefits of flavanol-rich cocoa appear to have been investigated in studies at the low end of the quality spectrum. Though the details are fuzzy, the report of the Cuna tribe seems to provide data from an observational study, a type of research that can hint at risk factors for disease or the benefits of certain lifestyle–but is incapable of determining cause and effect and usually crude in its ability to sort out important confounding variables that might also account for long lives or healthy brains. Observational trials have led doctors to support longstanding medical practices that later proved to be useless or even harmful when they were examined in more rigorous studies (e.g. routinely prescribing estrogen therapy to prevent heart disease in postmenopausal women). A second study of Dutch men appears to have similar limitations. Two additional studies mentioned in the news story did not directly test people with dementia or cardiovascular problems. One was conducted in apparently healthy mice. The study about blood flow in healthy women not only needs to be reproduced in people suffering from dementia (as the story notes), but to be relevant must also show that the increased blood flow can actually prevent, slow, or turn back dementia itself. The story doesn’t mention other potential therapies for dementia or cardiovascular disease.
The article does not mention costs of flavanol-rich cocoa or chocolate, nor does it compare their costs to other lifestyle or medical strategies for improving brain function and cardiovascular health. However, most people must recognize the generally-low cost of these products.
The article is short on details about quantifying the potential benefits of flavanol-rich chocolate. Precisely how great are the observed changes in the various studies? How long-lasting is the effect?
The article does not report on any specific side effects observed during these or other studies. However, it quotes a researcher speculating about a likely potential harm of eating chocolate—fattening up people with extra calories. The story also does not attempt to compare this potential harm to the known harms of other medical and surgical interventions for dementia or cardiovascular disease.
The article summarizes the apparently unpublished studies and musings of researchers attending a major medical conference. It notes some reservations (implied or explicit) about two of the studies (i.e. that the ability of flavanols to increase blood flow in healthy subjects must still be tested in individuals suffering with dementia; and that improved blood pressure and lower death rates of Dutch men could have been due to characteristics other than nibbling chocolate). Other important limitations of the research go unmentioned. (See "Summary" below.)
There are no obvious elements of disease-mongering.
The article cites numerous researchers and their affiliations, including a note that some of their research is supported by the candy-maker Mars, Inc.
There is no discussion of other treatment options for either dementia or cardiovascular disease.
The news story explains that cocoa or chocolate rich in flavanol (the ingredient purported to improve brain function and cardiovascular health) is not widely available in American stores.
The article rightly notes that “cocoa long has been studied for potential medical benefits.”
We can’t be sure whether the article relied solely or largely on a press release.
Systematic, Criteria-Driven
Questions to ask about new Alzheimer’s drug research by @KatKStone incl:
-does study focus on patient outcomes or surrogate markers?
-does study rely on selective subgroups? (yield more favourable outcomes)
-who were the patients? https://www.healthnewsreview.org/2017/08/6-questions-to-ask-when-writing-and-reading-about-new-alzheimers-research/#.YRw5xNVXths.twitter @HealthNewsRevu
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like